Esophageal and gastric cancer incidence and mortality in alendronate users

Journal of Bone and Mineral Research

Volumn 27, Issue 3, 2012, Pages 679-686

  Abrahamsen, Bo ^a,b   Pazianas, Michael ^c   Eiken, Pia ^d   Russell, R Graham G ^c,e   Eastell, Richard ^e  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d HILLERØD HOSPITAL   (Denmark)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

ADVERSE EFFECTS; ALENDRONATE; EPIDEMIOLOGY; ESOPHAGEAL CANCER; MORTALITY

Indexed keywords

ALENDRONIC ACID; ETIDRONIC ACID;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DYING; ENDOSCOPY; ESOPHAGUS CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; RISK REDUCTION; STOMACH CANCER; UPPER GASTROINTESTINAL TRACT;

ADULT; AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DENMARK; ESOPHAGEAL NEOPLASMS; ETIDRONIC ACID; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 84857347660     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1481     Document Type: Article

References (30)

1. Abid S, Mumtaz K, Jafri W, et al. Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy. 2005; 37: 740-4.
2. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333: 1437-43.
3. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348: 1535-41.
4. Castell DO., " Pill esophagitis"-The case of alendronate. N Engl J Med. 1996; 335: 1058-9.
5. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003; 115: 209-16.
6. Wysowski DK., Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360: 89-90.
7. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V., Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010; 341: c4444.
8. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ., Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010; 304: 657-63.
9. Solomon DH, Patrick A, Brookhart MA., More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360: 1789-90.
10. Abrahamsen B, Eiken P, Eastell R., More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360: 1789-2.
11. Wang Z, Bhattacharyya T., Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res. 2011 Mar; 26 (3): 553-60.
12. Díez-Pérez A, Hooven FH, Adachi JD, et al. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2011 May 14 (online).
13. Vial M, Grande L, Pera M., Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res. 2010; 182: 1-17.
14. Cadarette SM, Katz JN, Brookhart MA, et al. Comparative gastrointestinal safety of weekly oral bisphosphonates. Osteoporos Int. 2009; 20: 1735-47.
15. Vizcaino AP, Moreno V, Lambert R, Parkin DM., Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer. 2002; 99: 860-8.
16. Varela I, Pereira S, Ugalde AP, et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med. 2008; 14: 767-72.
17. Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA., Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011; 96 (4): 1006-14.
18. Bolland MJ, Grey AB, Gamble GD, Reid IR., Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab. 2010; 95: 1174-81.
19. Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010; 28: 3582-90.
20. Guenther A, Gordon S, Tiemann M, et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer. 2010; 126: 239-46.
21. Sassa S, Okabe H, Nemoto N, Kikuchi H, Kudo H, Sakamoto S., Ibadronate may prevent colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Res. 2009; 29: 4615-9.
22. Sewing L, Steinberg F, Schmidt H, Goke R., The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis. 2008; 13: 782-9.
23. Reszka AA, Halasy-Nagy J, Rodan GA., Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol. 2001 Feb; 59 (2): 193-202.
24. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK., Esophagitis associated with the use of alendronate. N Engl J Med. 1996 Oct 3; 335 (14): 1016-21.
25. Blank MA, Gibson GW, Myers WR, Dierckman TA, Phipps RJ, Smith PN., Gastric damage in the rat with nitrogen-containing bisphosphonates depends on pH. Aliment Pharmacol Ther. 2000 Sep; 14 (9): 1215-23.
26. Chen H, Fang Y, Tevebaugh W, Orlando RC, Shaheen NJ, Chen X., Molecular mechanisms of Barrett's esophagus. Dig Dis Sci. 2011 Oct 8.
27. Shimoyama S., Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemother Pharmacol. 2011 Apr; 67 (4): 729-39.
28. Koppert LB, Wijnhoven BP, van Dekken H, Tilanus HW, Dinjens WN., The molecular biology of esophageal adenocarcinoma. J Surg Oncol. 2005 Dec 1; 92 (3): 169-90.
29. Russell RG., Bisphosphonates: the first 40 years. Bone. 2011 Jul; 49 (1): 2-19.
30. Russell RG, Watts NB, Ebetino FH, Rogers MJ., Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun; 19 (6): 733-59.